CHEK2 and prostate carcinoma: Ideally, counselling should be based on synthesising all available data, using risk models such as BOADICEA/CanRisk that have been developed for breast, ovarian, and prostate cancer.49 50 It would be relatively straightforward to extend BOADICEA/CanRisk to incorporate the ovarian and prostate cancer risks associated with ATM and CHEK2 PTVs.